Developing select technologies
Arch Biopartners key technologies, scientists, publications and ongoing trials.
LSALT Peptide (Metablok), is the company’s lead drug candidate targeting organ inflammation in the lungs, liver and kidneys.
LSALT peptide trials and development
In 2023, the company produced new human safety and efficacy data in a Phase I dose escalation study and announced that it has received FDA permission to proceed with a new Phase II human trial targeting organ inflammation in other applications such as cardiac surgery-associated kidney injury (CS-AKI).
- June 2023, FDA permission to proceed with a new Phase II trial targeting CS-AKI.
- April 2023, successful completion of a Phase I dose escalation trial.
Previous Phase II and III trials during the pandemic accelerated Arch’s drug development plans and shortened the path toward the approval and commercialization of LSALT peptide. Inflammation in the lungs was a common complication of hospitalized pandemic patients and LSALT peptide was used for the first time in a Phase II trial to treat acute lung inflammation in that setting. Successful results accelerated LSALT peptide’s inclusion in a national Phase III trial in Canada looking for new treatments to treat acute lung inflammation in the later stages of the pandemic.
Find out more about our science platforms and about LSALT peptide development and human trials targeting organ inflammation.
An experienced group of scientists working together to develop the Arch science platforms.
Science and Research Teams
- Current work on LSALT Peptide is directed by Arch’s larger Treatments for Inflammation Team, led by Dr. Daniel Muruve Ph. D. (Arch Biopartners CSO), Dr. Justin Macdonald Ph. D., and Dr. Arthur Lau Ph. D (Arch Biopartners Project Director), who are primarily based at the University of Calgary.
- The DPEP1 Inflammation Pathway and LSALT Peptide (Metablok) were discovered by the Metablok team – Dr. Stephen Robbins Ph. D., Dr. Donna Senger Ph. D., Jennifer Rahn B Sc., M Sc. and their colleague Dr. Paul Kubes at the University of Calgary.
The Arch science team also includes:
- Dr. Randall Irvin Ph. D., Professor Emeritus at the University of Alberta, whose work on the BORG Peptide is not currently under commercial development.
The Arch Biopartners Science Teams have all participated and authored key papers and journal publications as a core part of their ongoing scientific research, discoveries and development.
- Treatments for Inflammation publications surrounding the development of LSALT Peptide (Metablok) as a treatment for inflammation with broad application to prevent organ and tissue injury
- AB569 publications describing AB569 as a novel bactericidal treatment for treatment resistant bacteria and Respiratory Pseudomonas
- BORG Peptide publications discussing a peptide-based biological coating for enhanced corrosion resistance, strength and control of adhesion of bacteria and microbes.
- Brain Tumor Stem Cell Targeting publications describe the development of a peptide-based delivery platform for targeting malignant brain tumors